Abel IP

Thomas P. Weber, Ph.D.



Thomas focuses his practice on representing clients from a broad spectrum of technology in all aspects of patent law. His experience includes:
  • Extensive in-house experience in industrial drug discovery and development for small-molecule pharmaceuticals.
  • Strong patent application preparation and prosecution experience in technological disciplines ranging from organic chemistry, polymers, advanced materials, cosmetics, drug discovery and development, and biological sciences, to semiconductor and LED manufacturing.
  • Freedom-to-operate and validity studies in support for strategic legal counseling, negotiations, business transactions, planning, licensing and venture capital investments.
  • Strong skills in legal and technical due diligence.

Prior to joining Abel IP, Thomas was a patent practitioner for six years with Greenblum & Bernstein PLLC, in the DC metro area.  There, he developed a close working relationship with the USPTO, interviewing Examiners regularly, and practicing with and mentoring under senior attorneys, many of whom were ex-Examiners from the USPTO. Previous to that, Thomas was a scientist in the drug discovery and development department at AstraZeneca R&D in Waltham, Massachusetts.

Area of Practice

  • Intellectual Property
  • Technology Transactions


  • Polymers
  • New Materials
  • Small-Molecule Pharmaceuticals
  • Synthetic Biology
  • Cosmetics
  • Medical Devices
  • Ceramics
  • Nanotechnology
  • Semiconductor Manufacturing


  • Licensed to practice before the U.S. Patent and Trademark Office
  • American Chemical Society
  • German Chemical Society (GDCh)


  • Ph.D. (Organic and Medicinal Chemistry), University of Houston, TX, 2002
  • J.D., The Catholic University of America, Columbus School of Law, Washington, D.C. 2010
  • Dipl. Chem., Universität des Saarlandes, Germany, 1997


  • Co-inventor of “Oxazolidinone and/or Isooxazoline derivatives as Antibacterial Agents” International Patent Appl. Pub. # WO 2004/048392 A1
  • Co-inventor of “Novel Rho Inhibitors” International Patent Appl. Pub. # WO 2004/004464 A1
  • First Author of “Metals in Rho-mediated processes: New leads for drug discovery”, Biochemistry 42, (2002), 9121-9126
  • First Author of “Metal Dependency for Transcription Factor Rho Activation” Biochemistry 42, (2002), 1652-1659
  • First Author of “The Mg2+ Requirements for Rho Transcription Termination Factor: Catalysis and Bicyclomycin Inhibition” Biochemistry 41, (2002), 12377-12383